rVA576

DRUG4 trials

Conditions

Bullous Pemphigoid (BP)Conjunctivitis, AllergicKeratoconjunctivitis, AtopicKeratoconjunctivitis, VernalParoxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

TerminatedNCT04037891

AKARI TherapeuticsConjunctivitis, Allergic, Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal

Start: 2019-03-04End: 2020-04-30Updated: 2025-04-10

Phase 2

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

CompletedNCT04035733

AKARI TherapeuticsBullous Pemphigoid (BP)

Start: 2018-09-25End: 2020-04-29Updated: 2025-04-22

Phase 3

Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576

CompletedNCT03588026

AKARI TherapeuticsParoxysmal Nocturnal Hemoglobinuria (PNH)

Start: 2018-06-07End: 2020-09-03Updated: 2025-04-09

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

TerminatedNCT03829449

AKARI TherapeuticsParoxysmal Nocturnal Hemoglobinuria

Start: 2017-03-13End: 2020-08-29Updated: 2025-04-10

Related Papers

Evaluation of Nomacopan for Treatment of Bullous Pemphigoid

JAMA Dermatology2022-05-0436 citations

Bullöses Pemphigoid: Ein small molecule zeigt großes Potenzial